Literature DB >> 27634692

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

U Nitz1, O Gluz2, J Huober2, H H Kreipe2, R E Kates2, A Hartmann2, R Erber2, Z Moustafa2, M Scholz2, B Lisboa2, S Mohrmann2, V Möbus2, D Augustin2, G Hoffmann2, E Weiss2, S Böhmer2, R Kreienberg2, A Du Bois2, D Sattler2, C Thomssen2, M Kiechle2, F Jänicke2, D Wallwiener2, N Harbeck2, W Kuhn2.   

Abstract

Entities:  

Year:  2017        PMID: 27634692     DOI: 10.1093/annonc/mdw349

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  1 in total

1.  Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008-2012.

Authors:  Malek Hannouf; Atul Batra; Sasha Lupichuk
Journal:  Curr Oncol       Date:  2021-03-04       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.